GlassScriptPhysician profile
Ashwin H Shah
NPI 1710983812
$19,026.41
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,349 · 2020: $4,468 · 2021: $2,302 · 2022: $2,057 · 2023: $21.67 · 2024: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $829 · Food and Beverage: $21.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $829.00 |
| Food and Beverage | $21.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Great Lakes Medical Services, LLC | $16,853.00 | 2019-2024 | |
| Astellas Pharma US INC | $362.43 | 2019-2022 | |
| Antares Pharma, INC. | $320.31 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $244.55 | 2019 | |
| Allergan, INC. | $204.78 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $133.67 | 2021-2022 | |
| Myovant Sciences INC. | $107.78 | 2021-2022 | |
| Blue Earth Diagnostics | $83.30 | 2019-2020 | |
| 180 Medical, INC. | $74.10 | 2021-2022 | |
| Clarus Therapeutics INC. | $69.85 | 2021 | |
| Urovant Sciences INC | $57.59 | 2021-2022 | |
| Boston Scientific Corporation | $57.09 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $55.43 | 2019-2021 | |
| Medtronic USA, INC. | $54.29 | 2019-2020 | |
| Hologic Sales and Service, LLC | $38.83 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $33.15 | 2019 | |
| Neotract INC. | $33.11 | 2019 | |
| Pfizer INC. | $31.31 | 2020 | |
| Teleflex LLC | $25.51 | 2022 | |
| Abbott Laboratories | $23.74 | 2022 | |
| Merck Sharp & Dohme LLC | $23.61 | 2022 | |
| Cook Medical LLC | $21.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.87 | 2022 | |
| Axonics, INC. | $18.11 | 2022 | |
| Mission Pharmacal Company | $18.02 | 2022 | |
| Coloplast Corp | $17.91 | 2022 | |
| Abbvie INC. | $17.67 | 2022 | |
| Convatec INC. | $14.16 | 2022 | |
| Acerus Pharmaceuticals Corporation | $11.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,668.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.